Myrexis, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.myrexis.com
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01285414
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸University of Texas Health Science Center at Houston, Houston, Texas, United States
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2010-04-01
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT01097070
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸Gary J. Richmond, MD, PA, Ft. Lauderdale, Florida, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
- Conditions
- HIV Infections
- Interventions
- Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR)Drug: 3-4 commercially available antiretroviral drugs
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2010-06-14
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT01026727
- Locations
- 🇺🇸
AIDS Healthcare Foundation Research Center, Beverly Hills, California, United States
🇺🇸Peter Wolfe, MD, PC, Los Angeles, California, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2010-01-06
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00967187
- Locations
- 🇦🇺
AIDS Research Initiative, Darlinghurst, New South Wales, Australia
🇦🇺Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia
🇦🇺St Vincent's Hospital, Darlinghurst, New South Wales, Australia
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
- Conditions
- Cancer
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2011-10-14
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00920205
- Locations
- 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
- Prev
- 1
- 2
- 3
- Next